TNFSF13B and chronic myelogenous leukemia, BCR-ABL1 positive: SDF-1 transcription was detectable from day 3, with a peak on day 7, and a decrease on day 14 of exposure to imatinib in cell cultures from R CML patients (Figure 4A); in turn, BAFF mRNA was transiently detectable on day 5 (Figure 4B).